Wet Age-Related Macular Degeneration (Wet AMD) - Epidemiology Forecast to 2032
![](/report_cover/8047/wet-age-related-macular-degeneration-wet-amd-epidemiology-forecast-to-2032_en.gif)
This report can be delivered to the clients within 5-7 Business Days
DelveInsight's 'Wet Age-Related Macular Degeneration (Wet AMD) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Wet Age-Related Macular Degeneration (Wet AMD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Geographies Covered
Wet Age-Related Macular Degeneration (Wet AMD) Understanding
The DelveInsight Wet Age-Related Macular Degeneration (Wet AMD) epidemiology report gives a thorough understanding of the Wet Age-Related Macular Degeneration (Wet AMD) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Wet Age-Related Macular Degeneration (Wet AMD) in the US, Europe, and Japan. The report covers the detailed information of the Wet Age-Related Macular Degeneration (Wet AMD) epidemiology scenario in seven major countries (US, EU5, and Japan).
Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Perspective by DelveInsight
The Wet Age-Related Macular Degeneration (Wet AMD) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Wet Age-Related Macular Degeneration (Wet AMD) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Wet Age-Related Macular Degeneration (Wet AMD) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Wet Age-Related Macular Degeneration (Wet AMD) Detailed Epidemiology Segmentation
The Wet Age-Related Macular Degeneration (Wet AMD) epidemiology covered in the report provides historical as well as forecasted Wet Age-Related Macular Degeneration (Wet AMD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
The DelveInsight Wet Age-Related Macular Degeneration (Wet AMD) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
Scope of the Report
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
The Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology report will allow the user to -
DelveInsight's 'Wet Age-Related Macular Degeneration (Wet AMD) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Wet Age-Related Macular Degeneration (Wet AMD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Wet Age-Related Macular Degeneration (Wet AMD) Understanding
The DelveInsight Wet Age-Related Macular Degeneration (Wet AMD) epidemiology report gives a thorough understanding of the Wet Age-Related Macular Degeneration (Wet AMD) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Wet Age-Related Macular Degeneration (Wet AMD) in the US, Europe, and Japan. The report covers the detailed information of the Wet Age-Related Macular Degeneration (Wet AMD) epidemiology scenario in seven major countries (US, EU5, and Japan).
Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Perspective by DelveInsight
The Wet Age-Related Macular Degeneration (Wet AMD) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Wet Age-Related Macular Degeneration (Wet AMD) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Wet Age-Related Macular Degeneration (Wet AMD) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Wet Age-Related Macular Degeneration (Wet AMD) Detailed Epidemiology Segmentation
The Wet Age-Related Macular Degeneration (Wet AMD) epidemiology covered in the report provides historical as well as forecasted Wet Age-Related Macular Degeneration (Wet AMD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
The DelveInsight Wet Age-Related Macular Degeneration (Wet AMD) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
Scope of the Report
- The Wet Age-Related Macular Degeneration (Wet AMD) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Report and Model provide an overview of the global trends of Wet Age-Related Macular Degeneration (Wet AMD) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight into the historical and forecasted patient pool of Wet Age-Related Macular Degeneration (Wet AMD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
- The report helps recognize the growth opportunities in the 7MM for the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Wet Age-Related Macular Degeneration (Wet AMD)
- The report provides the segmentation of the Wet Age-Related Macular Degeneration (Wet AMD) epidemiology
- 11-year Forecast of Wet Age-Related Macular Degeneration (Wet AMD) epidemiology
- 7MM Coverage
- Prevalent and Diagnosed Cases of Wet Age-Related Macular Degeneration (Wet AMD)
- Cases of Wet Age-Related Macular Degeneration (Wet AMD) by Mutation Types
- Wet Age-Related Macular Degeneration (Wet AMD) Cases associated with Clinical Manifestations
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Wet Age-Related Macular Degeneration (Wet AMD)?
- What are the key findings pertaining to the Wet Age-Related Macular Degeneration (Wet AMD) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
- What would be the total number of patients of Wet Age-Related Macular Degeneration (Wet AMD) across the 7MM during the forecast period (2019-2032)?
- Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
- What is the disease risk, burden and unmet needs of Wet Age-Related Macular Degeneration (Wet AMD)?
- What are the currently available treatments of Wet Age-Related Macular Degeneration (Wet AMD)?
The Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the global Wet Age-Related Macular Degeneration (Wet AMD) market
- Quantify patient populations in the global Wet Age-Related Macular Degeneration (Wet AMD) market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Wet Age-Related Macular Degeneration (Wet AMD) therapeutics in each of the markets covered
- Understand the magnitude of Wet Age-Related Macular Degeneration (Wet AMD) population by its epidemiology
- The Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
- Patient Segmentation
- Disease Risk & Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
1. KEY INSIGHTS
2. EXECUTIVE SUMMARY OF WET AGE-RELATED MACULAR DEGENERATION (WET AMD)
3. WET AGE-RELATED MACULAR DEGENERATION (WET AMD): DISEASE BACKGROUND AND OVERVIEW
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. PATIENT JOURNEY
5. EPIDEMIOLOGY AND PATIENT POPULATION
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
5.4.1. Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Scenario in Germany (2019- 2032)
5.5.2. France Epidemiology
5.5.2.1. Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Scenario in France (2019- 2032)
5.5.3. Italy Epidemiology
5.5.3.1. Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Scenario in Italy (2019- 2032)
5.5.4. Spain Epidemiology
5.5.4.1. Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Scenario in Spain (2019- 2032)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
5.6.1. Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Scenario in Japan (2019- 2032)
6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES
6.1. Wet Age-Related Macular Degeneration (Wet AMD) Treatment and Management
6.2. Wet Age-Related Macular Degeneration (Wet AMD) Treatment Algorithm
7. KOL VIEWS
8. UNMET NEEDS
9. APPENDIX
9.1. Bibliography
9.2. Report Methodology
10. DELVEINSIGHT CAPABILITIES
11. DISCLAIMER
12. ABOUT DELVEINSIGHT
*The table of contents is not exhaustive; will be provided in the final report
2. EXECUTIVE SUMMARY OF WET AGE-RELATED MACULAR DEGENERATION (WET AMD)
3. WET AGE-RELATED MACULAR DEGENERATION (WET AMD): DISEASE BACKGROUND AND OVERVIEW
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. PATIENT JOURNEY
5. EPIDEMIOLOGY AND PATIENT POPULATION
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
5.4.1. Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Scenario in Germany (2019- 2032)
5.5.2. France Epidemiology
5.5.2.1. Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Scenario in France (2019- 2032)
5.5.3. Italy Epidemiology
5.5.3.1. Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Scenario in Italy (2019- 2032)
5.5.4. Spain Epidemiology
5.5.4.1. Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Scenario in Spain (2019- 2032)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
5.6.1. Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology Scenario in Japan (2019- 2032)
6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES
6.1. Wet Age-Related Macular Degeneration (Wet AMD) Treatment and Management
6.2. Wet Age-Related Macular Degeneration (Wet AMD) Treatment Algorithm
7. KOL VIEWS
8. UNMET NEEDS
9. APPENDIX
9.1. Bibliography
9.2. Report Methodology
10. DELVEINSIGHT CAPABILITIES
11. DISCLAIMER
12. ABOUT DELVEINSIGHT
*The table of contents is not exhaustive; will be provided in the final report
LIST OF TABLES
List of Table:
Table 1: Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in 7MM (2019-2032)
Table 2: Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in the United States (2019-2032)
Table 4: Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in Germany (2019-2032)
Table 6: Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in France (2019-2032)
Table 8: Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in Italy (2019-2032)
Table 10: Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in Spain (2019-2032)
Table 12: Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in the United Kingdom (2019-2032)
Table 14: Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in Japan (2019-2032)
Table 16: Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in Japan (2019-2032)
List of Table:
Table 1: Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in 7MM (2019-2032)
Table 2: Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in the United States (2019-2032)
Table 4: Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in Germany (2019-2032)
Table 6: Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in France (2019-2032)
Table 8: Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in Italy (2019-2032)
Table 10: Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in Spain (2019-2032)
Table 12: Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in the United Kingdom (2019-2032)
Table 14: Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in Japan (2019-2032)
Table 16: Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in Japan (2019-2032)
LIST OF FIGURES
List of Figures
Figure 1 Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in 7MM (2019-2032)
Figure 2 Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in the United States (2019-2032)
Figure 4 Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in Germany (2019-2032)
Figure 6 Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in France (2019-2032)
Figure 8 Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in Italy (2019-2032)
Figure 10 Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in Spain (2019-2032)
Figure 12 Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in Japan (2019-2032)
Figure 16 Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report
List of Figures
Figure 1 Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in 7MM (2019-2032)
Figure 2 Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in the United States (2019-2032)
Figure 4 Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in Germany (2019-2032)
Figure 6 Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in France (2019-2032)
Figure 8 Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in Italy (2019-2032)
Figure 10 Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in Spain (2019-2032)
Figure 12 Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Wet Age-Related Macular Degeneration (Wet AMD) Epidemiology in Japan (2019-2032)
Figure 16 Wet Age-Related Macular Degeneration (Wet AMD) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report